US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

48.54

-1.3991-2.80%

Post-market: 48.570.0302+0.06%19:30 EDT

Volume:19.43K

Turnover:941.16K

Market Cap:46.11M

PE:- -

High:49.48

Open:49.46

Low:48.06

Close:49.94

52wk High:56.18

52wk Low:23.81

Shares:950.00K

Float Shares:950.00K

Volume Ratio:1.17

T/O Rate:2.05%

Dividend:0.65

Dividend Rate:1.35%

ROE:--

ROA:--

PB:1.04

PE(LYR):- -

Loading ...

Overview Company News Filings

Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

Amylyx announces Lucidity Phase 3 trial met primary endpoint

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

BNK Banking Corp Confirms CEO and CFO in Permanent Roles

Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Youcare Pharmaceutical Subsidiary Receives U.S. FDA Clearance for YKYY033 Injection Clinical Trial

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Upstream Bio reports Q2 revenue $773,000, consensus $377,250

UNITED LAB Receives FDA Clearance for Clinical Trial of Drug Candidate UBT48128

MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BBC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":48.5409,"timestamp":1789502400000,"preClose":49.94,"halted":0,"volume":19434,"hourTrading":{"tag":"盘后","latestPrice":48.5711,"preClose":48.5409,"latestTime":"19:30 EDT","volume":21,"amount":1012.5272,"timestamp":1789515005044,"change":0.0302,"changeRate":0.000622,"amplitude":0},"delay":0,"changeRate":-0.028015618742490932,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Closed","change":-1.3991,"latestTime":"09-15 16:00:00 EDT","open":49.46,"high":49.4763,"low":48.06,"amount":941157.13692,"amplitude":0.02836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":49.94,"sharesOutstanding":900004,"nav":49.991,"aum":47491296.56,"dividendRate":0.013477,"bidAskSpread":0.002112,"postHourTrading":{"tag":"盘后","latestPrice":48.5711,"preClose":48.5409,"latestTime":"19:30 EDT","volume":21,"amount":1012.5272,"timestamp":1789515005044,"change":0.0302,"changeRate":0.000622,"amplitude":0},"volumeRatio":1.167656,"impliedVol":0.3075,"impliedVolPercentile":0.3108},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.167656,"shares":950000,"dividePrice":0.6542,"high":49.4763,"amplitude":0.02836,"preClose":49.94,"low":48.06,"week52Low":23.81,"pbRate":"1.04","week52High":56.18,"institutionHeld":0,"latestPrice":48.5409,"eps":0,"divideRate":0.013477,"volume":19434,"delay":0,"ttmEps":0,"open":49.46,"prevYearClose":38.56,"prevWeekClose":49.3848,"prevMonthClose":53.05,"prevQuarterClose":52.6861,"fiveDayClose":53.17,"twentyDayClose":53.2599,"sixtyDayClose":45.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660425479","title":"Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425479","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425479?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:15","pubTimestamp":1787145349,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421486","title":"Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421486","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421486?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:30","pubTimestamp":1787142600,"startTime":"0","endTime":"0","summary":"August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347617/0/en/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","PFS","PSIL","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184678054","title":"Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184678054","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184678054?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:15","pubTimestamp":1787127336,"startTime":"0","endTime":"0","summary":"Andy Acker, Portfolio Manager for healthcare and biotech strategies at Janus Henderson Investors, notes that despite interest rates remaining higher than markets anticipated at the start of the year,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JDOC","IBBJ","IBB","BBC","IAI","IYG","BK4588","SPCK","MRNY","BK4582","BIS","MRNX","IJT","BBP","BIB","IWO","QSML","GTPE","BK4585","PBE","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499847","title":"Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499847?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:02","pubTimestamp":1787072575,"startTime":"0","endTime":"0","summary":"Vivoryon Therapeutics AG ( ($NL:VVY) ) has issued an announcement. Vivoryon Therapeutics N.V., a Germany-based clinical-stage biotech listed on Eur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","BBC","XBIX","BK4195","AGM","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461075","title":"Amylyx announces Lucidity Phase 3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461075","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461075?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:06","pubTimestamp":1787051213,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4007","AMLX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609102","title":"argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609102?lang=en_us&edition=fundamental","pubTime":"2026-08-17 13:39","pubTimestamp":1786945177,"startTime":"0","endTime":"0","summary":"arGEN X ( ($GB:0QW0) ) has shared an announcement. argenx has reported positive topline results from its ALKIVIA Phase 3 trial of VYVGART Hytrulo i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4139","SOCL","PSIL","BK4563","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410575","title":"Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410575?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:50","pubTimestamp":1786927814,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4006","PSIL","MSB","BK4139","BBC","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105196","title":"Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105196","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660105196?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:24","pubTimestamp":1786926259,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial testing ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","MESO","BK4139","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199823","title":"BNK Banking Corp Confirms CEO and CFO in Permanent Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199823","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659199823?lang=en_us&edition=fundamental","pubTime":"2026-08-14 08:32","pubTimestamp":1786667549,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BNK Banking Corporation Limited ( ($AU:BBC) ). BNK Banking Corporation Limited has made its interim leadership ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bnk-banking-corp-confirms-ceo-and-cfo-in-permanent-roles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bnk-banking-corp-confirms-ceo-and-cfo-in-permanent-roles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659660861","title":"Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2659660861","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659660861?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:31","pubTimestamp":1786638674,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. The Phase 1 trial A Phase 1 Trial, Evaluating the Safety and Tolerability ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0611395673.USD","LU2495084118.USD","BK1141","LU1719994722.HKD","603259","PSIL","XBIX","LU1046422090.SGD","WX","161027","APXH","MEDI","IE00BPRC5H50.USD","LU2488822045.USD","LU1808992512.USD","LU2045819591.USD","IDNA","IBRN","02359","LU0708995583.HKD","LU1770034418.SGD","BBC","LU1251922891.USD","PSCH","BK1583","LU1979443071.USD","FHLC","CXO","IE00B543WZ88.USD","LU2242644610.SGD","IE00B5MMRT66.SGD","BK1576","LU2328871848.SGD","LU1997245177.USD","LU1997244956.HKD","LU1303224171.USD","LU0348766576.USD","SMCO","BK0216","LU0456842615.SGD","SURI","LU0348767384.USD","LFSC","LU1969619763.USD","LU0700851271.USD","LU2125910500.SGD","LU0320764599.SGD","LU1934453819.USD","LU1997245094.SGD","BMED","LU0052750758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0516422440.USD","LU1242518931.SGD","LU0417516902.SGD","LU0039217434.USD","LU0128526141.USD","LU0348825331.USD","LU2495084118.USD","APXH","LU0348735423.USD","LU1251922891.USD","LU0348766576.USD","LU2039709279.SGD","603259","BK1589","02359","LU0051755006.USD","KURE","SMCO","IBRN","LU1808992512.USD","BK1141","SG9999002463.SGD","XBIX","LU0700851271.USD","PSIL","LU0516422366.SGD","LU0611395673.USD","02269","LU1720050803.USD","BK1521","LU0979878070.USD","LU0588546209.SGD","LU0516423091.SGD","LU3063872942.SGD","LU1997245094.SGD","LU2488822045.USD","LU0819121731.USD","LU1688375341.USD","CXO","LU0856984785.SGD","LU2125910500.SGD","LU0348767384.USD","LU0456842615.SGD","LU1719994722.HKD","IE00BPRC5H50.USD","LU1979443071.USD","BBC","LU0359202008.SGD","LU0326950275.SGD","IE00B0JY6N72.USD","FHLC","161027","LU0708995583.HKD","LU1934453819.USD","LU2045819591.USD","PSCH","LU0043850808.USD","LU0181495838.USD","LU1880383366.USD","LU0516423174.USD","LU1770034418.SGD","BK1610","LU0823426480.USD","LU2328871848.SGD","WX","BK1583","IDNA","LU0029874061.USD","LU0516422952.EUR","LU0327786744.USD","LU1046422090.SGD","LU1969619763.USD","MEDI","SG9999002562.SGD","LU1242518857.USD","LU2242644610.SGD","BK0216","LU0417516738.SGD","BMED","LU1997244956.HKD","LU0456827905.SGD","LU1997245177.USD","IE00B5MMRT66.SGD","SURI","LU0307460666.USD","LFSC","LU1794554557.SGD","LU1303224171.USD","03759","IE00B543WZ88.USD","LU0320764599.SGD","LU0572944931.SGD","BK1576","LU0359201612.USD","LU0140636845.USD","LU0456846285.SGD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185590","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659185590?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3344078/0/en/kailera-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","JDOC","BBC","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658700929","title":"NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658700929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658700929?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:08","pubTimestamp":1786540125,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs Inc., a clinical-stage biotech and majority-owned subsidiary of SciSparc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908647","title":"Altimmune Announces Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908647?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD  $519 million in cash, cas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343554/0/en/altimmune-announces-second-quarter-2026-financial-results-and-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1978683503.SGD","SG9999001440.SGD","LU0417517546.SGD","LU1242518857.USD","IR","LU1559883803.SGD","PSIL","LU0256863902.USD","ELF","LU0053671581.USD","LU0979878070.USD","LU0566484027.USD","BK4161","ALD","BK4588","BK4585","CROC","BK4183","LU0256863811.USD","LU1242518931.SGD","BBC","LU0124384867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178800852","title":"Youcare Pharmaceutical Subsidiary Receives U.S. FDA Clearance for YKYY033 Injection Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1178800852","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178800852?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:23","pubTimestamp":1786523005,"startTime":"0","endTime":"0","summary":"Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received notification from the U.S. Food...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945894","title":"Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945894","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945894?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:10","pubTimestamp":1786479000,"startTime":"0","endTime":"0","summary":"Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3343174/0/en/cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","NMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992421","title":"Upstream Bio reports Q2 revenue $773,000, consensus $377,250","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992421","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992421?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:15","pubTimestamp":1786446927,"startTime":"0","endTime":"0","summary":"“We continued to make progress toward the initiation of our Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027. Our End-of-Pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-reports-q2-revenue-773000-consensus-377250-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-reports-q2-revenue-773000-consensus-377250-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172660963","title":"UNITED LAB Receives FDA Clearance for Clinical Trial of Drug Candidate UBT48128","url":"https://stock-news.laohu8.com/highlight/detail?id=1172660963","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172660963?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:12","pubTimestamp":1786443159,"startTime":"0","endTime":"0","summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, United Biotechnology (Zhuhai Hengqin) Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) for its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3M56506.USD","BBC","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935473","title":"MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935473?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:50","pubTimestamp":1786362626,"startTime":"0","endTime":"0","summary":"07:45 EDT MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results Published first on TheFly – the ultimate source for real-tim...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-shares-drop-11-pre-market-after-q2-earnings-phase-3-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-shares-drop-11-pre-market-after-q2-earnings-phase-3-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","JOYT","DECU","FEBU","VOTE","VGFPF","RGLO","GXDW","BBC","PMDE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":141,"code":"91000000","status":"200"}]}}